Hikal Share Price
HIKAL
Hikal Share Price Chart
About Hikal
Hikal Financials
Market cap ₹4,846 Crs | Open ₹393.20 | Close ₹393.00 |
Circuit range ₹471.60 - ₹314.40 | Day range ₹386.05 - ₹397.50 | Year range ₹260.30 - ₹416.95 |
Volume 2,97,605 | Avg. traded ₹392.25 | Revenue (12m) ₹1,821 Crs |
Hikal Limited is a Mumbai-based chemicals company. It specialises in research, development and manufacturing of fine chemicals, agrochemicals and pharmaceutical intermediates.
In 1988, the company started manufacturing and selling chemicals, intermediates, medicines and insecticides. Hikal Chemical Industries Limited (HCIL) was a joint venture between the Hiremath family and Surajmukhi Investment and Finance Limited, a fully-owned subsidiary of Kalyani Steels Limited.
Hikal Limited became a full-fledged public limited company in 1994. The year 2000 saw the rebranding of Hikal Chemical Industries Ltd to Hikal Ltd. The company's plan to diversify into agrochemicals, pharmaceuticals and biotech is reflected in the name change. In 2005, Hikal Ltd and Crompton Corporation USA signed a long-term agreement to produce and supply a next-generation crop protection product.
In 2008, the company founded Acoris Research Ltd., a fully operational contract research facility situated at the International Biotech Park Pune. A year later in 2009, the company enhanced its manufacturing capabilities. The construction of a new multi-purpose plant for active ingredients in crop protection at the Taloja site, in Maharashtra, was successfully concluded. It commissioned several new multipurpose Active Pharmaceutical Ingredient (API) plants in Bangalore, which holds approval from the US Food and Drug Administration (FDA). A new multipurpose pharmaceutical intermediates plant was established in Panoli, Gujarat.
The market capitalisation of Hikal Limited is over ₹3,700 crore as of January 11, 2024. Hikal share price has gained over 70% in the last three years.
Business operations
Hikal’s business is divided into two segments – crop protection and pharmaceuticals, with a broad portfolio of goods and services to meet the client's changing demands. In its crop protection segment, the company combines research and technology, production skills and intellectual capital to deliver top-notch crop protection products, including insecticides, fungicides, herbicides, biocides and intermediates.
Hikal Limited provides active pharmaceutical ingredients, active ingredients and intermediates to international clients. Its facilities are also designed to cater to the customised requirements of clients in the United States, Europe and Japan. There was a substantial increase in its global customers in 2023 after the introduction of new products within the antidiabetic therapeutic category.
The crop protection division experienced a 12% annual revenue growth, reaching a total revenue of ₹907.9 crore in FY23. The pharmaceutical division reported revenues amounting to ₹1,115 crore during the same period.
The company operates five manufacturing facilities across India situated in Taloja and Mahad in Maharashtra, Panoli in Gujarat and Jigani in Karnataka. It also runs a research & technology centre in Maharashtra’s Pune. These facilities undergo regular inspections by multinational corporations and global regulatory authorities. Hikal's R&D has a comprehensive infrastructure that includes 11 synthetic laboratories, four analytical labs and one process intensification lab.
Financial highlights
– Hikal Limited's revenue from operations for FY23 stood at ₹2,023 crore, up by 4% compared to ₹1,943 crore in FY22.
– EBITDA (earnings before interest, taxes, depreciation, and amortisation) decreased to ₹262.5 crore as against ₹345.4 crore for the previous year, a decline of 24%.
– Hinal Limited’s profit after tax (PAT) of the company decreased to ₹78.4 crore as against ₹160.5 crore for the previous year, a decline of 51%.
— The earnings per share (EPS) for FY23 was ₹6.36 compared to ₹13.02 in the previous financial year.
Hikal Key indicators
52 week high ₹416.95 | 52 week low ₹260.30 | P/E ratio 66 |
P/B ratio 4 | ROE 5.99% | ROCE 7.82% |
Dividend yield 0.31% | Debt/Equity ratio 0.69 | EPS 5.64 |
Learn more
Sector
Equity returns
Dividend returns
Safety factor
Growth factor
Debt vs Equity
Profit factor
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily
Analyst ratings:
Analyst ratings:
100%
Hold
0%
Sell
0%
This analysis is based on the reviews of 2 experts in the last 7 days
Hikal Fundamentals
Hikal Financial Ratios
Operating profit margin15.1% | Net profit margin3.9% |
ROE5.99% | ROA2.85% |
ROCE7.82% |
Quick ratio0.88 | Current ratio1.28 |
Interest coverage2.69 | Asset turnover0.73 |
Debt to Equity0.69 |
P/E ratio66 | P/B ratio4 |
EV / EBITDA15.07 | |
Dividend yield0.31% |
Learn more
Revenue statement
All values are in ₹ Crores (Cr)Learn more
Cash flow
All values are in ₹ Crores (Cr)Learn more
Balance sheet
All values are in ₹ Crores (Cr)Total assets
Total liabilities
Learn more
Hikal Share Price history
Day | Open | Close | Change % |
---|---|---|---|
Tue, Nov 19 2024 | ₹398.40 | ₹393.00 | -1.71% |
Mon, Nov 18 2024 | ₹410.75 | ₹399.85 | -0.99% |
Thu, Nov 14 2024 | ₹394.90 | ₹403.85 | |
Wed, Nov 13 2024 | ₹388.50 | ₹387.20 | |
Tue, Nov 12 2024 | ₹376.00 | ₹384.65 | |
Mon, Nov 11 2024 | ₹388.85 | ₹376.55 | -2.69% |
Fri, Nov 8 2024 | ₹381.80 | ₹386.95 | |
Thu, Nov 7 2024 | ₹383.85 | ₹381.80 | -0.53% |
Events
Corporate actions
Dividend • ₹0.6/share
Ex date 04 Sep 2024
Dividend • ₹0.6/share
Ex date 20 Feb 2024
Dividend • ₹0.6/share
Ex date 18 Sep 2023
Dividend • ₹0.6/share
Ex date 14 Feb 2023
Dividend • ₹0.4/share
Ex date 14 Sep 2022
Dividend • ₹1.2/share
Ex date 23 Feb 2022
Learn more